Developers pursuing new strategies to improve trial efficiency: Tufts CSDD

By Alexandria Pesic

- Last updated on GMT

Related tags Pharmacology

Drug developers are pursuing new strategies to help improve the operational efficiency of their clinical trials, according to a panel of industry leaders recently convened by the Tufts Centre for the Study of Drug Development (CSDD) in Boston, US.

The panel, whose members were drawn exclusively from research-based companies, said they had begun collaborating with investigative sites in developing protocols and educating patients about trials before they agree to participate, in an attempt to streamline the trial process.

“The pharmaceutical and biotech industry is facing a crisis in that it needs to develop new drugs more quickly and control expenses,” ​said Tufts CSDD senior research fellow, Ken Getz.

“Developers understand that substantial operational improvements will more likely flow from new approaches that increase the probability of success, rather than from actions which merely seek to reduce or prevent failures.”

Site failure

According to Tufts CSDD, more than two-thirds of trial sites fail to meet their patient enrolment targets. And, whereas in 2001 nearly half of all screened patients completed trials, in 2010 that figure plummeted to less than one in four.

Getz says some of the blame may lie in the ever increasing number of procedures patients are subjected to, with the median number per trial sky rocketing by 49 per cent between 2000-03 and 2004-07.

“Improving patient enrolment and controlling the number of procedures could provide substantial benefits,” ​he said.

Sponsor communication

The industry leaders convened by Tufts also agreed that communication between sponsors and investigative sites – before, during and after trials – remains critical to the development of good relations.

In addition, medical advisors to help sites better understand trial goals, testing protocols with patients prior to trials, and using electronic medical records to help define and manage data flow, were all agreed by the panel to be of paramount importance to a trial’s success.

Related news

Show more

Related products

show more

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Content provided by Formedix | 17-Apr-2023 | White Paper

Companies often have to conduct multiple clinical trials at the same time, which means they've got to be efficient, and compliant with industry regulations....

Related suppliers

Follow us


View more